$0.9395
-0.0325-3.35%
Last update: Nov 10, 3:40 PM
Ocugen Inc
OCGNNASDAQ
Ocugen fell 28.0% from $1.35 to $0.97, behind the S&P 500's +10.5%. Its worst day was Sep 9 (−19.9%), and its low came Oct 30 at $0.70.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patientsMALVERN, Pa., Jan.
+18.7% · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
EPS of $-0.06 beat the $-0.06 estimate on $-193,000.00 revenue (est. $1.1M).
+5.4% · S&P 500 +0.7%
Ocugen closed at its highest level of the year, 83.7% above where the year started.
+6.0% · S&P 500 −0.6%
EPS of $-0.06 missed the $-0.05 estimate on $1.5M revenue (est. $526,512.00).
−19.5% · S&P 500 +0.8%
EPS of $-0.07 missed the $-0.05 estimate on $1.5M revenue (est. $986,664.00).
−3.1% · S&P 500 −0.2%
Ocugen shares fell 19.9%, while the S&P 500 fell 0.5%.
−19.9%, the year's worst day · S&P 500 −0.5%
EPS of $-0.06 missed the $-0.05 estimate on $2.0M revenue (est. $914,000.00).
+17.4% · S&P 500 +1.7%
Where it ended: a close of $0.97 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 3, 2027 (EPS est. $-0.05, revenue est. $1.1M).
Nothing in the past 12 months.
All OCGN dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for OCGN and SPY from Benzinga historical bars. Not investment advice.
